Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495062 | 0.85 | WEE1 (0.50) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL6498760 | 0.84 | WEE1 (0.48) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL6202618 | 0.78 | WEE1 (0.36) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL7252385 | 0.78 | WEE1 (0.36) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL6504952 | 0.68 | WEE1 (0.41) | WEE1ALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL6504264 | 0.68 | PTGDR2 (0.41) | WEE1CHEK1ALDH1A1TDP1 | |
| SCHEMBL6498347 | 0.68 | TDP1 (0.61) | WEE1CHEK1SRCPIK3CAMTOR | |
| SCHEMBL6503691 | 0.68 | TDP1 (0.40) | WEE1CHEK1HPGDHSD17B10TDP1 | |
| SCHEMBL6505761 | 0.68 | PTGDR2 (0.41) | WEE1CHEK1ALDH1A1TDP1 | |
| SCHEMBL6505751 | 0.68 | PTGDR2 (0.41) | WEE1CHEK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | disclosed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | WEE1 1065/4885CHEK1 1422/4885SRC 904/4885 |
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | WEE1 3618/4885CHEK1 4552/4885SRC 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.